State Public Health Department officials have recommended over $7 million dollars in grant funding to pay for a series of state-sponsored clinical trials to assess the safety and efficacy of cannabis and cannabinoids.
The proposed studies include a pair of clinical trials to evaluate the use of cannabidiol (CBD), a nonpsychotropic plant cannabinoid, for patients with pediatric epilepsy. Two additional trials will assess the use of cannabis for patients suffering from post-traumatic stress. Other studies will assess the efficacy of either cannabis or CBD in the treatment of Parkinson’s disease, brain tumors, ulcerative colitis, and pain management. (More specific summaries of all eight proposed studies are available online here.)
Grant funding for the proposed studies requires final approval by the state Board of Health in December.
Following funding approval, researchers will still be required to gain additional federal approval in order to obtain access to research-grade cannabis or CBD.
The state of California previously sponsored a similar series of clinical trials assessing the safety and efficacy of marijuana. Those studies evaluated the use of whole-plant cannabis in patients with neuropathy, multiple sclerosis, and autoimmune deficiencies. A summary of those trials, published in 2012, concluded, “Based on evidence currently available the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.”
The political and cultural victories for the marijuana legalization movement continue to accumulate as new developments lead us closer to the ultimate goal of full legalization. Just in the last couple of weeks, we’ve seen the powerful, unambiguous endorsement of full legalization by the most influential newspaper in America: The New York Times.
That endorsement was followed by a series of six follow-up editorials explaining in more detail precisely why the Times decided to join the fight to end prohibition. Additionally, The Brookings Institution, a highly respected Washington, DC think tank, published a very favorable report card on the first six months of the legal sales of marijuana in Colorado.
These were both significant events, because they involved respected institutions known for their careful and thorough analysis of important public policy issues. Neither has a history of backing a pro-pot agenda, so their support both elevates the issue and makes a strong argument for regulation.
More than six out of ten Americans – including majorities of self-identified Democrats, Independents, and Republicans – support the regulation and retail sale of marijuana in Colorado, according to the findings of a nationwide HuffPost.com/YouGov poll released today.
Colorado voters in 2012 approved a statewide initiative legalizing the personal consumption and cultivation of the plant. The measure also allows for the state-licensed commercial production and retail sales of cannabis to those over the age of 21. Commercial cannabis sales began on January 1st of this year. To date, these sales have generated nearly $11 million in tax revenue.
Sixty-one percent of Americans – including 68 percent of Democrats, 60 percent of Independents, and 52 percent of Republicans – say they “support” Colorado’s efforts to regulate the commercial cannabis market. Only 27 percent of respondents oppose the Colorado law.
Respondents between the ages of 18 and 29 (65 percent) as well as those age 65 and older (64 percent) were most likely to support Colorado’s efforts, while those between the ages of 45 to 65 (55 percent) were less likely to do so.
The results of a separate poll of Colorado voters commissioned by Quinnipiac University in April similarly reported that most Coloradoans support the state’s efforts to regulate marijuana sales and consumption.
Similarly licensed commercial retail sales of cannabis began last week in Washington state.
In response to a separate HuffPost/YouGov poll question, 54 percent of those surveyed said that the US government should not enforce federal anti-marijuana laws in states that have legalized and regulated the plant. Only 29 percent of respondents endorsed the notion of enforcing federal prohibition in states that are pursuing alternative regulatory schemes.
“Every day in America, hundreds of thousands of people engage in transactions involving the recreational use of marijuana, but only in two states – Colorado and Washington – do these transactions take place in a safe, above-ground, state-licensed facility where consumers must show proof of age, the product sold is of known quality, and the sales are taxed in a manner to help fund necessary state and local services,” NORML Deputy Director Paul Armentano said. “Not surprisingly, most Americans prefer to have cannabis regulated in this sort of legal setting as opposed to an environment where the plant’s production and sale is entirely unregulated and those who consume it are stigmatized and classified as criminals.”
Complete poll results are available online here.
State lawmakers have approved legislation, Senate Bill 155, to fund observational and clinical research assessing the safety and therapeutic efficacy of cannabis. Democrat Gov. John Hickenlooper signed the bill into law today.
The measure establishes a subaccount of up to $10 million within the state’s medical marijuana program fund to be utilized specifically for the purpose of conducting state-sponsored cannabis research. The intent of this new research program is to “gather objective scientific research regarding the efficacy of administering marijuana and its component parts as part of medical treatment.” The law also establishes a ‘scientific advisory council,’ which may include expert participants from around the nation, to evaluate research proposals and make recommendations in regards to funding requests.
“SB 155 invests the dollars collected from medical marijuana fees into a meaningful effort to study the therapeutic and medical benefits of the drug,” stated Democrat Rep. Crisanta Duran, a co-sponsor of the bill, told The Huffington Post. “Patients will benefit from this investment and Colorado will become a national leader in developing medical marijuana research.”
In recent years, only one state — California — has previously earmarked state funding to explicitly sponsor clinical cannabis research. That program, established at various universities statewide, funded numerous clinical trials over the past decade evaluating the efficacy of whole-plant cannabis for a variety of conditions, including multiple sclerosis and neuropathic pain. A review of these trials published in The Open Neurology Journal concluded, “Based on evidence currently available the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.”
Earlier this month, the US Drug Enforcement Administration (DEA) publicly announced in the Federal Register that it is increasing its marijuana production quota from 21 kilograms to 650 kilograms (about 1,443 pounds) in order to meet increasing demand for the plant from clinical investigators.
Federal regulations permit a farm at the University of Mississippi to cultivate set quantities of cannabis for use in federally approved clinical trials. Regulators at the DEA, the US Food and Drug Administration, PHS (Public Health Service), and the US National Institute on Drug Abuse must approve any clinical protocol seeking to study the plant’s effects in human subjects — including those trials that are either state or privately funded.
Colorado voters do not have buyers’ remorse.
The majority of Colorado voters believe that legalizing cannabis has been “good” for the state and 54 percent say they support the new laws regulating the plant’s retail production and sale, according to the results of a Quinnipiac University poll released today.
Fifty-five percent of voters approved Amendment 64 in November 2012, which allows for the personal possession and cultivation of cannabis by those age 21 and older. Separate provisions in the measure also allow for the state-licensed commercial production and retail sale of cannabis and cannabis-infused products. Retail cannabis sales began on January 1 of this year.
Other results released by the Quinnipiac University poll include:
49 percent of voters admit they’ve tried marijuana, but only 15 percent admit using it since it became legal January 1;
Driving has not become more dangerous because of legalized marijuana, voters say 54 – 39 percent;
Legalized marijuana will save the state and taxpayers a significant amount of money, voters say 53 – 41 percent;
Legalized marijuana will have a positive impact on the state’s criminal justice system, voters say 50 – 40 percent;
Legalized marijuana “increases personal freedoms in a positive way,” voters say 53 – 44 percent;
Legalized marijuana has not “eroded the moral fiber” of people in Colorado, voters say 67 – 30 percent.
A strong majority of Democrats (69 percent) and Independents (56 percent), but not Republicans (28 percent) said that the passage of marijuana legalization has been good for the state.
The Quinnipiac poll possesses a margin of error of +/- 2.7 percentage points.